Lv1
90 积分 2025-01-18 加入
Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial
1天前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
3天前
已完结
Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study
3天前
已完结
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
1个月前
已完结
Chemotherapy in EGFR-mutated NSCLC: optimizing combinations with TKIs and amivantamab
1个月前
已完结
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
1个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
1个月前
已完结
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study
2个月前
已完结
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study
2个月前
已完结
皖公网安备34019202002308
